Treatments Against RA and Effect on FDG-PET/CT
Public ClinicalTrials.gov record NCT02374021. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In a randomized controlled clinical trial, investigators will compare the effects on \[18F\]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) from two treatment regimens in rheumatoid arthritis (RA) patients deemed methotrexate inadequate responders (MTX-IRs). Two common RA treatments will be compared: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus tumor necrosis factor (TNF) inhibitor (etanercept or adalimumab, plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening).
Study identification
- NCT ID
- NCT02374021
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Interventions
- Methotrexate Drug
- Sulfasalazine Drug
- Hydroxychloroquine Drug
- Etanercept Drug
- Adalimumab Drug
Drug
Eligibility (public fields only)
- Age range
- 45 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2016 (Type not available)
- Primary completion
- May 2021 (Actual)
- Completion
- May 2021 (Actual)
- Last update posted
- Oct 26, 2022
2016 – 2021
United States locations
- U.S. sites
- 31
- U.S. states
- 16
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Loma Linda University Clinical Trial Center | Loma Linda | California | 92354 | — |
| David Geffen School of Medicine at UCLA | Los Angeles | California | 90095 | — |
| Brigid Freyne, MD Inc. | Murrieta | California | 92563 | — |
| Desert Medical Advances | Palm Desert | California | 92260 | — |
| University of California San Francisco | San Francisco | California | 94110 | — |
| Nazanin Firooz MD, Inc. | West Hills | California | 91307 | — |
| Robert W. Levin, MD, PA | Clearwater | Florida | 33765 | — |
| IRIS Research and Development | Plantation | Florida | 33324 | — |
| Southwest Florida Clinical Research Center | Tampa | Florida | 33609 | — |
| University of Kentucky | Lexington | Kentucky | 40508 | — |
| The Center for Rheumatology and Bone Research | Wheaton | Maryland | 20902 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Northwell Health | Great Neck | New York | 11021 | — |
| New York University School of Medicine | New York | New York | 10003 | — |
| Mount Sinai- Icahn School of Medicine | New York | New York | 10029 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Oregon Health & Science University | Portland | Oregon | 97329 | — |
| Altoona Research Center | Duncansville | Pennsylvania | 16635 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15261 | — |
| Metroplex Clinical Research Center | Dallas | Texas | 75231 | — |
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | — |
| Baylor Scott & White Medical Center- Temple | Temple | Texas | 76508 | — |
| Seattle Rheumatology Associates | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02374021, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2022 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02374021 live on ClinicalTrials.gov.